DOI: https://doi.org/10.22141/2224-0721.6.54.2013.84634

Новые возможности профилактики сахарного диабета 2-го типа

K.A. Zuyev, D.G. Kogut

Abstract


Согласно официальным данным Министерства здравоохранения Украины на 01.01.2013, наше государство завершило 2012 год с официально зарегистрированным общим количеством больных сахарным диабетом (СД) 1 303 157 человек [1]. Эта цифра сама по себе не может не впечатлять своей значительностью. Однако общеизвестно, что эти данные не отражают реальной численности людей, живущих с этим заболеванием в нашей стране. По данным некоторых эпидемиологических исследований, проведенных в Украине в последнее время, на каждого выявленного пациента с СД приходится 2–3 невыявленных, то есть людей, которые даже не подозревают о том, что им уже следовало бы начать лечение во избежание развития тяжелых диабетических осложнений [2].


References


Официальные данные МЗ Украины (http://www.moz.gov.ua).

Маньковский Б.Н. Частота выявления новых случаев сахарного диабета 2-го типа и эффективность сахароснижающей терапии у впервые выявленных пациентов: результаты исследования DIABETTER // Ліки України. — 2011. — № 10(156). — С. 14-19.

Williams R., Airey M., Baxter H. et al. Epidemiology of diabetic retinopathy and macular oedema: a systematic review // Eye (Lond). — 2004. — 18(10). — P. 963-983.

De Boer I.H., Rue T.C., Hall Y.N. et al. Temporal trends in the prevalence of diabetic kidney disease in the United States // JAMA. — 2011 Jun 22. — 305(24). — P. 2532-2539.

Boulton A.J. The diabetic foot: grand overview, epidemiology and pathogenesis // Diabetes Metab. Res. Rev. — 2008. — Vol. 24, Suppl. 1. — S. 3-6.

Diabetes and Cardiovascular Disease. A Statement for Healthcare Professionals From the American Heart Association // Circulation. — 1999. — Vol. 100. — P. 1134-1146.

The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // N. Engl. J. Med. — 2008. — Vol. 358. — P. 2560-2572.

The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes // N. Engl. J. Med. — 2008. — Vol. 358. — P. 2545-2559.

Duckworth W., Abraira C., Moritz T. et al. Glucose control and vascular complications in veterans with type 2 diabetes // N. Engl. J. Med. — 2009. — Vol. 360. — P. 129-139.

Lindström J., Ilanne-Parikka P. et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: The follow-up results of the Finnish Diabetes Prevention Study // Lancet. — 2006. — Vol. 368. — P. 1673-1679.

Li G., Zhang P., Wang J. et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study // Lancet. — 2008. — 371. — P. 1783-1789.

The Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin // N. Engl. J. Med. — 2002. — 346. — P. 393-403.

Diabetes Prevention Program Research Group, Knowler W.C., Fowler S.E., Hamman R.F. et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study // Lancet. — 2009. — 14(374). — P. 1677-1686.

Chiasson J.L., Gomis R., Hanefeld M. et al. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus // Diabetes Care. — 1998. — 21(10). — P. 1720-1725.

The DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial // Lancet. — 2006. — 368. — P. 1096-1105.

Carlsson L.M.S., Peltonen M., Ahlin S. et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects // N. Engl. J. Med. — 2012. — 367. — P. 695-670.

Adams T.D., Gress R.E., Smith S.C. et al. Long-term mortality after gastric bypass surgery // N. Engl. J. Med. — 2007. — 357. — P. 753-61.

American Diabetes Association: Standards of Medical Care in Diabetes // Diabetes Care. — 2012. — 35. — S11-S63.

Pournaras D.J., Aasheim E.T., Sovik T.T. et al. Effect of the definition of type II diabetes remission in the evaluation of bariatric surgery for metabolic disorders // Br. J. Surg. — 2012. — 99(1). — P. 100-103.

Torgerson J.S., Hauptman J., Boldrin M.N., Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients // Diabetes Care. — 2004. — 27(1). — P. 155-61.

Reaven G.M. Banting lecture 1988: role of insulin resistance in human disease // Diabetes. — 1988. — 37. — P. 1595-1607.

Reddy K.J., Singh M., Bangit J.R., Batsell R.R. The role of insulin resistance in the pathogenesis of atherosclerotic cardiovascular disease: an updated review // J. Cardiovasc. Med. — 2010. — 11. — P. 633-47.

Sowers J.R. Insulin resistance and hypertension // Am. J. Physiol. Heart Circ. Physiol. — 2004. — 286. — H1597-H1602.

Vaidyula V.R., Rao A.K., Mozzoli M. et al. Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand // Diabetes. — 2006. — 55. — P. 202-208.

Holman R.R., Sanjoy K.P., Bethel M.A. et al. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes // N. Engl. J. Med. — 2008. — 359. — P. 1577-1589.

Golovchenko I., Goalstone M.L., Watson P. et al. Hyperinsulinemia enhances transcriptional activity of nuclear factor-kappaB induced by angiotensin II, hyperglycemia, and advanced glycosylation end products in vascular smooth muscle cells // Circ. Res. — 2000. — 87. — P. 746-752.

Worthley M.I., Holmes A.S., Willoughby S.R. et al. The deleterious effects of hyperglycemia on platelet function in diabetic patients with acute coronary syndromes mediation by superoxide production, resolution with intensive insulin administration // J. Am. Coll. Cardiol. — 2007. — 49(3). — P. 304-310.

Montagnani M., Chen H., Barr V.A., Quon M.J. Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179) // J. Biol. Chem. — 2001. — 276(32). — P. 30392-30398.

Goldstein B.J., Mahadev K., Wu X. Redox paradox: insulin action is facilitated by insulin-stimulated reactive oxygen species with multiple potential signaling targets // Diabetes. — 2005. — 54(2). — P. 311-321.

Dandona P., Chaudhuri A., Ghanim H., Mohanty P. Proinflammatory effects of glucose and anti-inflammatory effect of insulin: relevance to cardiovascular disease // Am. J. Cardiol. — 2007. — 99. — 15B-26B.

Malmberg K., Ryden L., Hamsten A. et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year // J. Am. Coll. Cardiol. — 1995. — 26. — P. 56-65.

The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia // N. Engl. J. Med. — 2012. — 367. — P. 319-328.

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) // Lancet. — 1998. — 352. — P. 837-853.

Gerstein H., Yusuf S., Riddle M.C. et al. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention) // Am. Heart J. — 2008. — 155. — P. 26-32.

Dailey G., Strange P. Lower severe hypoglycemia risk: insulin glargine versus NPH insulin in type 2 diabetes // Am. J. Manag. Care. — 2008. — 14(1). — P. 25-30.

Rosenstock J., Dailey G., Massi-Benedetti M. et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes // Diabetes Care. — 2005. — 28. — P. 950-955.

Inzucchi S.E., Bergenstal R.M., Buse J.B. et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) // Diabetes Care. — 2012. — 35(6). — P. 1364-79.

Garber A.J., Abrahamson M.J., Barzilay J.I. et al. AACE Comprehensive Diabetes Management Algorithm // Endocr. Pract. — 2013. — 19(№ 2). — P. 327-336.

American Diabetes Association Standards of Medical Care in Diabetes-2013 // Diabetes Care. — 2013. — Vol. 36, Suppl. 1.






Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2019

 

   Seo анализ сайта